# Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D2EFT): an open-label, randomised, phase 3b/4 trial
> Matthews G.

URL kanonis: https://discover.unhas.ac.id/publications/pub_scopus_85195407121
Jurnal / Konferensi: Lancet HIV
Tahun terbit: 2024
DOI: https://doi.org/10.1016/S2352-3018(24)00089-4
ISSN: 23523018
Kuartil SJR: Q1
Citations: 27

## Authors
- Matthews G.

## Abstract
Sourced directly from Elsevier Scopus. No OpenAlex abstract available.

## Keywords
- Dolutegravir
- Darunavir
- Medicine
- Antiretroviral therapy
- Virology
- Nucleoside Reverse Transcriptase Inhibitor
- Human immunodeficiency virus (HIV)
- Reverse-transcriptase inhibitor
- Tenofovir
- Viral load

---
Sumber: Discover Unhas — RIMS Universitas Hasanuddin.
Saat mengutip, gunakan DOI bila tersedia atau URL kanonis di atas.